CGA 369 Intellectual Holdings

CGA 369 Intellectual Holdings is a private biotechnology company focused on the development of novel small molecule therapeutics for neurodegenerative diseases. The company's lead research effort centers on CGA-369, an orally active compound designed to target and disrupt the formation of toxic amyloid-beta oligomers associated with Alzheimer's disease. By preventing the aggregation of these proteins, the company aims to protect neuronal integrity and restore cognitive function in affected patients. Based in Florida, the entity primarily functions as an intellectual property holding and research vehicle, advancing its candidates through the pre-clinical pipeline. The company seeks to address the significant unmet medical need in dementia and memory loss through innovative molecular design.